Abstract
Multiple myeloma is a significant cause of mortality worldwide, and although changes in the treatment landscape have improved outcomes overall, many patients become refractory to standard therapies. In Latin America, outcomes are especially poor, further compounded by access and equality barriers. Belantamab mafodotin is a novel antibody-drug conjugate, targeting anti-B-cell maturation antigen. Two recent phase 3 trials, DREAMM-7 and DREAMM-8, have demonstrated notable efficacy with belantamab mafodotin combination regimens in patients with relapsed/refractory multiple myeloma. Ocular adverse events were also observed in these studies, as anticipated with antibody-drug conjugates containing monomethyl auristatin F. If belantamab mafodotin is approved for use in clinical practice, healthcare professionals will need clear, region-appropriate guidance on the management of ocular adverse events. A multidisciplinary panel of experts from Argentina, Brazil, Colombia, and Mexico was established, comprising 13 specialists in hematology/oncology and ophthalmology. The panel established a set of practical recommendations to address key clinical questions relating to identification of ocular events, management strategies, multidisciplinary collaboration, and patient-centric care. These recommendations were developed through detailed discussion, review of available evidence, and experience in clinical trials, and are intended to support healthcare professionals across Latin America in the treatment of patients with relapsed/refractory multiple myeloma.